The stock of First Wave BioPharma Inc. (NASDAQ:FWBI) last traded at $3.78, up 6.48% from the previous session.
Data from the available sources indicates that First Wave BioPharma Inc. (NASDAQ:FWBI) is covered by 2 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $126.00 and a low of $126.00, we find $126.00. Given the previous closing price of $3.55, this indicates a potential upside of 3449.3 percent. FWBI stock price is now -19.59% away from the 50-day moving average and -82.40% away from the 200-day moving average. The market capitalization of the company currently stands at $3.67M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
In total, 0 analysts have assigned it a hold rating, and 2 have given it a buy rating. Brokers who have rated the stock have averaged $126.00 as their price target over the next twelve months.
.
A total of 12.66% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in FWBI stock. A new stake in First Wave BioPharma Inc. shares was purchased by ARMISTICE CAPITAL, LLC during the first quarter worth $159,000. ACADIAN ASSET MANAGEMENT LLC invested $27,000 in shares of FWBI during the first quarter. In the first quarter, SUSQUEHANNA INTERNATIONAL GROUP, LLP acquired a new stake in First Wave BioPharma Inc. valued at approximately $8,000. GEODE CAPITAL MANAGEMENT, LLC acquired a new stake in FWBI for approximately $6,000. ADVISOR GROUP HOLDINGS, INC. purchased a new stake in FWBI valued at around $1,000 in the second quarter. In total, there are 15 active investors with 2.00% ownership of the company’s stock.
With an opening price of $4.0300 on Thursday morning, First Wave BioPharma Inc. (NASDAQ: FWBI) set off the trading day. During the past 12 months, First Wave BioPharma Inc. has had a low of $3.01 and a high of $289.80. The fifty day moving average price for FWBI is $4.7006 and a two-hundred day moving average price translates $21.4776 for the stock.
The latest earnings results from First Wave BioPharma Inc. (NASDAQ: FWBI) was released for Sep, 2022. According to the Biotechnology Company, earnings per share came in at $18.2, beating analysts’ expectations of -$21.07 by 39.27. This compares to -$683.15 EPS in the same period last year. The company reported revenue of $-4.39 million for the quarter, compared to $30.4 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -114.44 percent.
First Wave BioPharma Inc.(FWBI) Company Profile
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties; and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn’s disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
